Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone.
Fudala PJ, Bridge TP, Herbert S, Williford WO, Chiang CN, Jones K, Collins J, Raisch D, Casadonte P, Goldsmith RJ, Ling W, Malkerneker U, McNicholas L, Renner J, Stine S, Tusel D; Buprenorphine/Naloxone Collaborative Study Group.
Fudala PJ, et al. Among authors: tusel d.
N Engl J Med. 2003 Sep 4;349(10):949-58. doi: 10.1056/NEJMoa022164.
N Engl J Med. 2003.
PMID: 12954743
Free article.
Clinical Trial.